Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)

This study has been withdrawn prior to enrollment.
(Award was ended by NIH for parent study)
National Heart, Lung, and Blood Institute (NHLBI)
New England Research Institutes
Information provided by (Responsible Party):
Ravi Thadhani, Massachusetts General Hospital Identifier:
First received: October 8, 2013
Last updated: June 27, 2014
Last verified: June 2014
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)